Allergy immunotherapy, more commonly referred to as
allergy shots, is the most effective treatment available for environmental allergies.
By reducing your reactions to pollens, pet dander, molds and dust mites,
allergy shots reduce symptoms and your need for medication. While it is a
highly effective treatment, immunotherapy does not contain medication and is
composed of natural protein extracts from allergens. By giving gradually
increasing doses of the allergen, immunotherapy teaches your immune system to
tolerate exposure to the allergens in the environment. It is highly effective
in treating sinus and eye symptoms along with asthma, sinusitis and allergy
induced eczema. To assure that proper treatment is provided, immunotherapy
should always be prescribed by a board certified allergist. Certification by
the American Board of Allergy, Asthma and Immunology assures that your doctor
has received at least 2 years of additional training specifically in treating
allergic diseases. Only through this intense training can a doctor gain
full knowledge of immunotherapy treatment.
While immunotherapy is the cornerstone of the allergy
specialty, not all allergy shots are created equally. Allergy Partners strives
to provide the most effective, safe and cost effective care possible.
Allergy Partners was founded on a simple premise: by working together,
allergists can identify and implement best practices, which will result in
improved patient care. By following this premise we have grown to over 100
allergists across the United States, and our shared knowledge and experience is
unsurpassed in allergy and asthma care. We have applied this knowledge to
create a state of the art immunotherapy program. To produce optimal results,
immunotherapy protocols must follow national guidelines which are based on the
latest research. These guidelines include proper patient selection, allergy
testing, and immunotherapy dosing. As the leader in allergy and asthma
care, Allergy Partners has compiled the largest collection of data and
information about allergy shots in the world. We are continually utilizing this
experience to further improve patient care. Furthermore, our Clinical
Excellence committee continually reviews the medical literature and assures
that our treatment program is state of the art.
The Allergy Partners immunotherapy protocols strictly
adhere to national practice guidelines and were developed in collaboration with
nationally recognized experts. To maintain the highest quality standards
throughout the immunotherapy treatment process, we compound our immunotherapy
extract at our centralized lab in Asheville, NC. Our lab was planned and
built in collaboration with industry experts and the FDA Center for Biologics
Evaluation and Research. Today we produce over a quarter of a million vials
annually of the highest quality allergy extract possible. Allergy
Partners extract labs strictly follows USP 797 guidelines for sterile
allergenic extract processing, and it is through this attention to detail that
we can provide you will be provided safe and effective treatment.
We invite you to learn more about
Allergy Partners, the conditions we treat and our immunotherapy treatment
program by browsing our website or contacting your local Allergy Partners
It is estimated that food allergy affects approximately 5%
of adults and 8% of children, with peanut allergy nearing approximately 2% of
the population. A peanut allergy is when the immune system makes a type of
antibody called IgE towards specific proteins in peanut. When a person with
peanut allergy is exposed to these peanut proteins, the peanut specific IgE
antibodies cause allergy cells (mast cells, basophils, eosinophils, etc.) to
create an allergic reaction. The symptoms of an IgE mediated allergic reaction
generally happen within minutes to two hours after exposure to the food and can
include: itching, flushing, hives, swelling, difficulty breathing, repeated
coughing, chest tightness, wheezing, hoarseness, change in voice, dizziness,
weakness, fainting, low blood pressure, nausea, vomiting, abdominal
cramps, or diarrhea. Such reactions can be life threatening.
The history of a previous reaction is one of the most important
diagnostic tools in determining if an IgE mediated food allergy is present. If
the history is consistent with an IgE mediated food allergy (timing and
symptoms), then further testing may be needed to confirm this allergy, or to
determine if a patient has grown out of their food allergy. The gold standard
for food allergy diagnosis is an oral food challenge, which is when the food
thought to cause an allergic reaction is given to the patient in a medical
facility in small increments and increased until either an allergic reaction
occurs, or a serving size is reached. Realistically, however, this is
mainly performed to rule out a food allergy, and is performed if the likelihood
of having an IgE mediated food allergy reaction is low. In order to determine
the likelihood of an IgE mediated food allergy the following tests are
available: specific IgE towards peanut, peanut component testing to proteins in
peanut (Ara h 1, 2, 3, 8 and 9), and skin prick testing. Screening with panels
of different food IgE’s without a previous history of a reaction to that food
is poorly informative, and should not be done for routine evaluation of
allergy. This is because a positive serum food specific IgE test may show
sensitization, but not necessarily clinical allergy. This is an important
distinction because a patient may have an elevated serum IgE to a food and have
no allergic reaction when eating this food.
Skin prick testing is usually done first, as it is a less
invasive test. Sometimes specific serum IgE to peanut is also obtained to
determine the likelihood of IgE mediated peanut allergy. The level that is
considered to be associated with a clinical allergy is different for each food.
Peanut component testing may also be helpful. This looks at the specific IgE
levels of different peanut proteins. If the Ara h 8 level is elevated, this is
associated with less likelihood of a clinical allergy to peanut, whereas
elevated IgE levels to Ara h 1, 2, and 3 are associated more with clinical
allergy. It is important to have a board certified allergist evaluate these
tests and determine if an oral food challenge is warranted.
The current approach to managing peanut allergy is avoidance
and treating allergic reactions promptly and appropriately. However, there are
ongoing trials to investigate the potential of treating peanut allergy. The
most promising trials include: Oral Immunotherapy (OIT), Sublingual Immunotherapy
(SLIT), Epicutaneous Immunotherapy (EPIT), and a Chinese herbal formula.
OIT has been studied the longest (more than 10 years) and has shown both short
term and longer-term responses to therapy. However, it does have its
limitations due to safety issues. In one trial, after receiving 4g of peanut
for 5 years through OIT, 50% of subjects passed an oral food challenge and were
able to re-incorporate peanut into their diets. The most limiting side effect
from OIT is that 10-15% experience gastrointestinal symptoms that prevent the
continuation of therapy. Other more severe symptoms have also been reported.
SLIT is similar to OIT, but smaller doses of allergen are administered under
the tongue. This has been shown to have fewer side effects than OIT. In one study,
after 44 weeks of therapy, 70% of patients were able to consume 5g of peanut
powder, or at least 10-fold more peanut powder than at baseline. EPIT uses
delivery of peanut allergen to the skin, called a peanut patch. A large study
is currently ongoing for the peanut patch in the United States and Europe. No
safety concerns have been noted after 11 months of EPIT. A Chinese herbal
formal is also being investigated that has shown no significant side effects.
Peanut allergy diagnosis and determining if a patient has
out-grown this allergy can be difficult and requires specialized training from
a board certified allergist. At Allergy Partners, all of our physicians are
board certified or eligible allergists and we stay up to date with the latest
in diagnostics and treatment.
Partners physician would likely respond to the above statement with a cautious
“maybe.” Hives, like many of the responses of the body, can be caused by
many stimuli, not just allergies. Take, for instance, the similar example
of sneezing. Sneezing is a common allergic symptom; however, we all know
that non-allergic stimuli can cause sneezing, from infections due to the common
cold to irritants in the air (pepper, for example). In a likewise fashion, hives
can be due to allergic and non-allergic causes.
Partners doctor will take a careful history and perform a thorough examination
when considering whether your hives are due to an allergic reaction. Be
prepared to answer questions on how long your symptoms have lasted, any recent
exposures to new foods or medications, and whether you have experienced any
If you have had
hives almost daily for six weeks or more, your allergist may use the term
“chronic” to describe your condition. Hives lasting less than six weeks
are called “acute”. The distinction between “acute” and “chronic” is
important, as acute hives are more frequently associated with identifiable
causes. If supported by the details of your history, allergy testing may
be helpful in identifying causes of acute hives.
non-allergic conditions have been reported to be associated with chronic hives,
including various infections, connective tissue diseases, thyroid dysfunction,
and endocrine disorders. If your symptoms do not readily suggest one of
these conditions, extensive laboratory testing is not typically warranted or
necessary. Extensive testing is not cost-effective and does not appear to
improve patient outcomes. In light of an unremarkable clinical history
and physical examination, laboratory evaluation and allergy testing rarely
identifies a cause for chronic hives.
Hives can be
incredibly uncomfortable and frustrating. Hives typically improve with a
regimen of antihistamines, regardless of the cause. For cases of chronic
hives that do not respond to antihistamines, alternative treatments are
available. A newly approved approach to chronic hives utilizes the medication
Xolair (omalizumab). This medication was initially developed for patients suffering
from moderate to severe allergic asthma, but has shown to be effective in
chronic hives. With your input, your Allergy Partners physician can decide what
testing and treatment options are best for you.
Nobody likes getting a shot, especially children.
However, US health guidelines recommend annual influenza vaccination of
children, especially those with asthma, and including those with egg allergy.
Live attenuated influenza vaccine (LAIV) is an intranasal vaccine administered
via the nose licensed for use in children. However, this vaccine contains egg
protein and it is currently suggested that it not be used on children with egg
allergy. Furthermore, North American guidelines recommend against its use in
children with asthma. Thus, asthmatic or egg allergic children receive a
traditional flu shot.
In a study recently published online by The Journal of Allergy and Clinical
Immunology (JACI), Turner and colleagues present the results of the
SNIFFLE-1 Study. In this study, 433 doses of LAIV intranasal flu
vaccine were administered to 282 children with egg allergy. Two thirds of
the children also had a physician diagnosis of asthma/recurrent wheezing and
41% had experienced a prior anaphylactic (severe allergic) reaction to egg.
The study found that influenza vaccination using LAIV was safe in egg-allergic
children – including those with a prior history of anaphylaxis – with no
systemic allergic manifestations seen. Eight children experienced mild short
lived symptoms, which may have been due to an IgE-mediated allergic
reaction. However, noting the intranasal reaction thresholds to egg, the
authors suggest these reactions were not likely to have been caused by egg
protein and were probably due to other ingredients in the vaccine.
Importantly, in those children with a history of asthma or recurrent wheezing,
there was no significant increase in respiratory symptoms requiring medical
treatment in the 72 hours following vaccination with LAIV. This suggests that
the current guidelines may be unnecessarily over-restrictive in terms of this
vaccine’s use in patients with asthma or egg-allergy. This study may help lead
to changes in the current guidelines and make an annual flu vaccine more
pleasant for kids with asthma and egg allergy.
have become an increasing public health issue. Recent studies now indicate that
nearly 1 in 13 children are diagnosed with food allergy. Food allergies are
triggered when the immune system make a special type of antibody, called IgE,
directed against foods. On re-exposure to the food, the IgE antibody can
trigger severe, even life threatening allergic reactions.
The diagnosis of
food allergy is typically done through a combination of a detailed medical
history coupled with specific food allergy testing. Classically, such testing
is through skin prick testing where a small amount of the food is applied to
the skin and the skin is then pricked with a small sterile probe, allowing the
liquid to seep under the skin. After about 20 minutes, a hive (a bump similar
to a mosquito bite) may form indicating allergy. More recently, a blood based
test commonly referred to as RAST or Immunocap testing has grown increasingly
popular. Unfortunately, these blood based tests can be overly sensitive and
have false positive results. This can lead to misdiagnosis of food allergy
which leads to unnecessary food avoidance, unnecessary medication
prescriptions, and increased cost.
In a recent
study in Journal of Pediatrics, Bird and colleagues at the University of
Texas Southwestern Medical Center and Dell Children’s Medical Center in Dallas
reviewed the charts of 797 patients referred for evaluation of possible food
allergy. They selected patients in whom the primary care provider had ordered a
standard panel of food-specific IgE tests. Such a panel was done in 284 (35%)
of all patients. Of these, only 90 patients (32.8%) had a history that
warranted such testing.
altered in 126 of patients based on the initial testing. Of these, 72 did not
have histories suggestive of food allergy and all of these individuals were
found to not have food allergy. In total, 112 (88.9%) of the 126 patients who
were avoiding foods were able to reintroduce at least one food. It was
estimated that the cost associated with those patients whose history did not
warrant food allergy testing was $79, 412.
The diagnosis of
food allergy hinges on a detailed history and physical exam. Food-specific IgE
testing is a vital tool used to confirm food allergy. This study, however,
highlights that panels of food specific IgE tests have little utility as a
screening tool. Such panels often result in the over-diagnosis of food allergy.
A ‘positive’ test does not automatically translate into clinical food allergy,
as a significant proportion of individuals with a positive test are not
Partners physicians are Board Certified Allergist-Immunologists. This means
that they have undergone two to three years of specialized training in the
diagnosis, treatment and management of allergic diseases, including food
allergy. They have expertise in the interpretation of food allergy test results
and are equipped to offer food challenges which are the definitive test for the
diagnosis of food allergy. If you are concerned about food allergy, contact
your Allergy Partners physician.
Source: Bird JA,
Crain M, Varshney P. Food Allergen Panel Testing Often Results in Misdiagnosis
of Food Allergy. J Pediatrics 2014:166(1):97-100.
Food allergies are due to an immune system reaction that occurs
soon after eating a certain food. They affect about one in twenty
Americans, with cases occurring at any age, but most commonly in babies and
young children. While any food may cause an allergic reaction, eight types of
food account for about 90 percent of food allergies: milk, egg, soy, wheat, peanuts,
tree nuts, shellfish and fish.
of a food allergy vary significantly from person to person, as does the amount
of food needed to trigger an allergic reaction. While most food-related
symptoms occur within two hours of ingestion, in some rare cases, the reaction
may be delayed by four to six hours or even longer. Common symptoms of a
food-related allergic reaction include: digestive
problems, hives or swollen airways. The most severe allergic reactions
may result in anaphylaxis, which can impair breathing, cause a dramatic drop in
blood pressure, and affect heart rate to a fatal degree.
patients may experience an itching and/or tingling feeling in their mouths
after consuming certain fruits, which is referred to as pollen-food allergy
syndrome or oral allergy syndrome. For example, patients allergic to birch
pollen can have this reaction when eating an apple. In rare cases, pollen-food
allergy syndrome can lead to anaphylaxis.
diagnosis of a food allergy generally requires a thorough medical history of
the patient including what and how much you ate, how long it took for symptoms
to develop, what symptoms you experienced and how long it lasted. Your doctor
may order skin and/or blood tests in making a diagnosis. However,a “positive”
result on any one test is not an absolute indication of a food allergy.
Allergists rely on their experience to properly interpret the results of tests
within the overall context of the patient’s medical history and properly
diagnose a food allergy. If you suspect you have a food allergy, talk to your
Allergy Partners physician to determine what method of diagnosis is most
this test, a tiny amount of liquid containing suspected food is placed on the
skin of your arms or back. The skin is then pricked with a small sterile probe,
allowing the liquid to seep under the skin. After about 20 minutes, a hive (a
bump similar to a mosquito bite) may form and will be compared to the bump at
the site of the control, where a liquid not containing any allergen is placed.
blood test (commonly known as RAST or ImmunoCAP) detects the presence of
allergen-specific antibodies known as
immunoglobulin E (IgE) antibodies. Additionally, a relatively new test,
called a “component test” can be ordered to gain more specific information and
is mostly used for peanut allergies. Blood tests have been used extensively but
often are not specifically based on patients’ detailed diet diary. When not
properly utilized, the results of a blood test can be very confusing and may
lead to unnecessary food restriction. Allergy Partners allergists use their
experience to determine when a blood test may be helpful and to properly
interpret the results of the blood test.
are a number of non-standardized tests that are advertised as helping diagnose
food allergy. These tests include allergen-specific IgG blood tests, antigen
leukocyte cellular antibody tests, hair analysis, and applied kinesiology.
Their use in the diagnosis of food allergy is not advised.
an oral food challenge, small increment amounts of food are fed to the patient
over a period of a few hours to determine if a reaction occurs. Due to the
possibility of a severe reaction, it must be conducted under medical
supervision by an experienced doctor and in a facility with emergency
medication and equipment on hand. The gold standard for a food challenge is one
that is double-blind and placebo-controlled, though it may still have very good
diagnostic value when lacking these conditions.
allergies can be challenging and stressful, so knowing what you or your child
is eating is an important first step. If you have doubts about a possible food
allergy, err on the side of caution until you have a chance to speak with an
Allergy Partners physician.
Sleep apnea is a common disorder in which you have one or more pauses in
breathing or shallow breaths while you sleep. Breathing pauses can last from a
few seconds to minutes and they may occur 30 times or more an hour. Typically,
normal breathing then starts again, sometimes with a loud snort or choking
sound. Sleep apnea usually is a chronic (ongoing) condition that disrupts your
sleep. As a result, the quality of your sleep is poor, which makes you tired
during the day. Sleep apnea is a leading cause of excessive daytime sleepiness.
More importantly, sleep apnea can increase your risk of high blood pressure,
heart attack, stroke, diabetes and obesity.
There is evidence
suggesting that a relationship exists between asthma and obstructive sleep
apnea. A recent study in the Journal of the American Medical
Association investigated if having asthma increased the risk of developing
obstructive sleep apnea (The
Association between Asthma and Risk of Developing Obstructive Sleep Apnea. JAMA
2015: 313 (2):156-164.).
This study used a population that consisted
of adults who had overnight sleep studies completed at 4 year intervals
starting in 1988 (The Wisconsin Sleep Cohort Study). Asthma and additional
information was assessed during these studies through March 2013.
The results found that participants with
bronchial asthma had a significantly higher incidence of developing obstructive
sleep apnea (27%) at their first 4 year follow up interval sleep study, versus
16% of the participants without asthma who developed sleep apnea at that
interval. Using all 4 year interval studies, there was also a significantly
higher percentage of participants with bronchial asthma who developed
obstructive sleep apnea (27% ), versus 17% of non-asthmatic participants who
developed obstructive sleep apnea.
In summary this study found that
preexistent asthma was a risk factor for an asthmatic patient developing
clinically relevant obstructive sleep apnea over a 4 year period. It was also
found that the longer the time a patient had bronchial asthma, the more likely
that the patient would develop obstructive sleep apnea.
Therefore, obstructive sleep apnea should
be considered in asthmatic patients with symptoms suggestive of sleep apnea,
and especially those patients who have a history of long-standing bronchial
asthma. Symptoms of sleep apnea include snoring, choking or gasping while
sleeping, daytime sleepiness, or not feeling well rested after sleep.
Identifying and treating obstructive sleep apnea in asthmatic patients has been
found to be beneficial, since another study has shown that treating obstructive
sleep apnea in patients with asthma leads to improvement in asthma symptoms,
improved air movement and improved quality of life.
If you think you have a sleep problem, consider keeping a
sleep diary for 1 to 2 weeks. Bring the diary with you to your next doctor’s
appointment. Write down when you go to sleep, wake up, and take naps. Also
write down how much you sleep each night, how alert and rested you feel in the
morning, and how sleepy you feel at various times during the day. This
information can help your doctor figure out whether you have a sleep disorder.
SLIT is an alternative method of allergen desensitization in
the management of atopic conditions such as asthma and allergic rhinitis, which
does not involve a series of injections. The protocol for SLIT involves
an allergist determining a patient’s sensitizing allergens, typically by skin
testing, followed by small doses of these allergens placed under the tongue
daily in the form of tablets or drops. This causes a decrease in the
body’s natural production of specific allergic antibody, called IgE.
Though SLIT is widely accepted and standard in Europe, not
all SLIT therapy is approved in the US by the Food and Drug Administration
(FDA). A tablet form of SLIT for patients with grass and ragweed allergy
(GRASTEK, ORALAIR, RAGWITEK) has been FDA approved and is currently available
for physicians to prescribe. While yet to be approved by the FDA,
sublingual drop therapy formulated by your Allergy Partners physician is
available for “off label” use.
Does it Work?
There is mounting evidence that SLIT is an effective treatment
strategy in the management of allergic conditions. A recent systematic
review in the Journal of the American Medical Association states: “The overall evidence provides a moderate grade level of
evidence to support the effectiveness of sublingual immunotherapy for the
treatment of allergic rhinitis and asthma, but high-quality studies are still
needed to answer questions regarding optimal dosing strategies.”1Though
evidence supports SLIT being more efficacious compared to some traditional
treatment strategies, it is very clear that subcutaneous injection
immunotherapy (allergy shots) is favorable to SLIT in reducing allergy
What Are the Side Effects?
In general, SLIT is well tolerated. Patients may have
oral itching or mild tongue swelling after the first 3-4 doses. However,
these symptoms typically subside. Other potential side effects
include: trouble breathing, throat tightness, throat swelling, dizziness,
rapid heartbeat, severe stomach cramps, vomiting, diarrhea, and severe flushing
of the skin. As there is risk for anaphylaxis, all patients on SLIT
therapy should have access to an epinephrine pen and be trained on its use and
the first dose of SLIT is administered in a physician’s office.
Is it For Me?
There are certainly advantages to SLIT. Published data
does demonstrate clinical efficacy and you can expect to see improvement in
your allergy symptoms. For patients with busy schedules, SLIT makes
immunotherapy less cumbersome as treatment can be given at home. For
children with “needle phobia,” SLIT provides an alternative option to avoid
weekly injections. Although allergy shots are the most efficacious form
of immunotherapy, there undoubtedly is a role for SLIT in the management of
allergic disease. Talk to your Allergy Partners physician about whether
SLIT is the best option for management of your allergy symptoms.
Sublingual immunotherapy for the treatment of
allergic rhinoconjunctivitis and asthma: a systematic review. JAMA. 2013 Mar
Food allergy is estimated to affect 5 to 7% of infants and 1
to 2% of adults. Currently there is no cure for food allergy and patients must
adhere to a strict regimen of dietary avoidance of foods to which they are
allergic. Despite the best of intentions, accidental exposure to food allergens
remains a significant cause of allergic reactions. To avoid such exposure, food
allergic patients and their families rely on food package labels to identify possible
The Food Allergy Labeling and Consumer Protection Act of
2004 requires packaged foods sold in the United States to clearly list the
eight primary food allergens in plain English on the ingredient label. These 8
foods are milk, egg, wheat, soybean, peanut, tree nuts, fish and shellfish.
However, for foods that may accidentally contain small amounts of allergens-
such as being produced in a factory that handles the allergen- precautionary
labels may be applied to food products as well. Such precautionary labeling is
neither consistent nor regulated. Food allergic patients have varying levels of
tolerance to allergens and such precautionary labels could lead to confusion
and unnecessary risk taking behavior.
In January, Medical News Today reported on a study published
in the Journal of Allergy and Clinical Immunology (January 2015) by the
research team led by Clare Mills, PhD of the Institute of Inflammation and
Repair at the University of Manchester in the UK. Researchers sought to better
define the threshold doses of 5 major food allergens (peanut, hazelnut, celery,
fish and shrimp) in a European population. What researchers were able to
demonstrate was that for these foods there is threshold dose below which only
10% of allergic subjects will react. Though more research is needed, such new
data could help better identify allergen doses that are safe versus those doses
which may trigger a reaction. This information would help improve patient
safety through refined product labeling.
These new findings highlight how essential it is for
patients with suspected food allergy to be evaluated by an allergist who will
not only assess but help minimize the risk for future food reactions.
“Study identifies levels at which five foods may
trigger allergic reactions” Medical News Today. January 2015.
Mills C et al. How much is too much?: Threshold
dose distributions for 5 food allergens. J Allergy Clin Immunol 2014, published
online January 2015, abstract.
Peanut allergy can result in severe, and at times fatal,
allergic reactions. Unfortunately, peanut allergy has become more and more
common over the years. A new study, however, gives hope that early
interventions may decrease the risk of developing peanut allergy.
A recent study published in the New England Journal of
Medicine suggests that early exposure to peanuts helps to prevent peanut
sensitization in high risk children. The study was performed in response
to the significant increase in the incidence of peanut allergy worldwide,
especially in westernized countries, such as the United States. The most
recent recommendations by the American Academy of Pediatrics (AAP) came in
2000, in response to outcomes from infant feeding trials conducted in Europe
and the United States. At that time, the AAP recommended refraining from
introduction of peanuts to children until age 3. Despite this recommendation,
the incidence of peanut allergy continues to rise, and in 2008, the AAP
retracted its recommendation due to insufficient evidence. Since that
time, multiple observational studies have found that early introduction of
peanut protein, as well as cow's milk and egg, result in decreased incidence of
these food allergies.
In a new study by Du Toit et al., Learning Early about
Peanut Allergy (LEAP), investigators studied over 500 infants at high risk of
peanut allergy (severe eczema, egg allergy, or both). Half of the
children were randomly selected to consume peanuts and the other half, to avoid
peanuts. At age 5, the children underwent peanut challenge to determine
if they were allergic. Results indicated that the prevalence of peanut
allergy in the peanut-avoidance group was significantly higher at 17.2%,
compared to 3.2% in the group that consumed peanuts.
The trial went on to compare two groups: one group of
infants with skin prick test (SPT) that was initially negative to peanut, and
another with mildly positive results (wheal of 1-4mm). Infants with a
wheal of >4mm were excluded from the study (about 10%). In infants
with an initially negative SPT, prevalence of peanut allergy was 13.7% in the
avoidance group and 1.9% in the consumption group. For infants with
mildly positive SPT, the prevalence of peanut allergy was 35.3% in the
avoidance group and 10.6% in the consumption group.
Although many questions still remain, early testing of
infants at high risk for peanut allergy in the first 4-8 months of life, along
with early introduction of peanut protein or in-office peanut challenge may
have the potential to prevent peanut allergy in the future.
Allergy Partners’ board certified allergists are experts in
the diagnosis and treatment of food allergies. If you have questions regarding
food allergies, contact your local Allergy Partners physician.
Welcome to our blog site! Stay tuned to get the latest news. We
will share tips and techniques for living with and managing your Allergies &
Asthma. We look forward to sharing useful resources with our patients!